Hanyu Medical Secures RMB 100 Million Series B Funding Led by Yingke Capital to Advance ValveClamp for Minimally Invasive Mitral Regurgitation Treatment

VCBeat (WeChat ID: vcbeat) has learned that Hanyu Medical recently completed a RMB 100 million Series B financing round. The round was led by Yingke Capital, with participation from Yueyin Medical Fund, Hetang Venture Capital, and existing shareholder Lize Fund.

Founded in 2016, Hanyu Medical is a company dedicated to the research and development, manufacturing, and sales of interventional medical devices for heart valves. Its core product, ValveClamp, is designed for minimally invasive interventional treatment of mitral regurgitation. The product holds fully independent domestic patents and has filed international PCT patent applications.

With the onset and acceleration of population aging in China, the incidence of cardiovascular disease is rising, with a large number of patients suffering from mitral regurgitation. Currently, the only effective treatment for moderate-to-severe mitral regurgitation is open-heart surgery. However, this approach has significant drawbacks, including high invasiveness, elevated risk, substantial pain, and slow recovery. Consequently, many patients do not receive treatment due to excessively high surgical risks.

Hanyu Medical’s core product, the ValveClamp mitral valve intervention device, is used for minimally invasive interventional treatment of mitral regurgitation. VCBeat has learned that the ValveClamp procedure differs from traditional open-heart surgery and current thoracoscopic minimally invasive surgeries. It does not require thoracotomy or incision into the heart, nor does it require cardiac arrest. Instead, a 3-cm incision is made in the precordial region, through which the device is delivered via cardiac puncture to perform the procedure. This approach constitutes an “ultra-minimally invasive surgery performed on a beating heart.”

ValveClamp

ValveClamp is expected to become the first minimally invasive interventional medical device for treating mitral regurgitation to be widely marketed in China, and the second such device globally, with a projected market launch in 2020.

Currently, Abbott’s MitraClip remains the only mature, minimally invasive device approved globally for the treatment of mitral regurgitation. Public information from Abbott and results from large-scale clinical studies have confirmed the safety and efficacy of the MitraClip, with its indications continuously expanding. The MitraClip is poised to become a significant growth driver for Abbott.

In contrast, no minimally invasive interventional devices for mitral regurgitation have yet been marketed in China. In July 2018, Handu Medical’s ValveClamp was used to perform the world’s first transapical mitral valve clipping procedure at Zhongshan Hospital in Shanghai, with the final case of its exploratory clinical trial completed by the end of that year. Multicenter, large-sample clinical trials are scheduled to commence next year, positioning ValveClamp as a strong candidate to become the first approved interventional device for mitral valve treatment in China.

Upon the completion of this round of financing, the Company will accelerate the market launch of its ValveClamp product and strengthen the research and development of new products.

List of Domestic Cardiac Valve Interventional Medical Device Companies

Founded in 2010, Yingke Capital is a professional institution specializing in Pre-IPO investment strategies and the only firm in China that has consistently focused on Pre-IPO investments. It is hailed as China’s “King of Pre-IPO” and the “Factory for Corporate Listings.” Four listed companies serve as cornerstone investors in Yingke Capital, while numerous large financial institutions and listed companies are limited partners (LPs) in funds managed by Yingke.

Yueyin Medical Fund is widely recognized as one of the most professional healthcare investment firms in the industry. A review of its previous portfolio companies—including Meiermu Ophthalmology, Lanhai Zhilue, Zhenluo Technology, Genetron Health, Ruihua Kangyuan, Purui Biotechnology, Health界 (Healthjie), Mingyi Zhudao, The Lancet Doctor, Shuchuang Robotics, Kaipu Imaging, and Tiankeya Biotechnology—reveals a consistent adherence to the same “focused expertise” investment thesis.

Lotus Hill Ventures, established in 2001, is the investment and management platform for technology transfer and commercialization at Tsinghua University. It focuses on incubating and investing in the commercialization of Tsinghua University’s scientific and technological achievements, covering fields such as information technology, life sciences, and clean technology.